EL7.AI
StocksMedium•29 March 2026•
1 min read

Bristol Myers Squibb Reports Positive Phase 3 Camzyos Data for Adolescents

Key Facts

1The Phase 3 SCOUT-HCM trial demonstrated the efficacy and safety of Camzyos (mavacamten) in adolescents with symptomatic obstructive hypertrophic cardiomyopathy (oHCM).
2Data was presented at the American College of Cardiology (ACC) conference, reinforcing the drug's safety and efficacy profile in a younger demographic.

Bristol Myers Squibb (BMS) has announced positive results from its Phase 3 SCOUT-HCM trial, evaluating Camzyos in adolescents with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). The data, presented at the American College of Cardiology (ACC) conference, confirms the drug's efficacy and safety in a younger patient demographic. Currently approved for adults, this successful trial supports the company's efforts to expand the clinical indications for the cardiovascular treatment. The findings reinforce Camzyos's position as a key growth driver within the BMS portfolio. Analysts view this development as a positive step toward securing regulatory approval for a broader patient base. This expansion could potentially increase the long-term market share of the drug in the global cardiology sector.